T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mondelez International
MDLZ
|
+$841M |
| 2 |
Liberty Global Class C
LBTYK
|
+$752M |
| 3 |
Apple
AAPL
|
+$720M |
| 4 |
Tesla
TSLA
|
+$713M |
| 5 |
NXP Semiconductors
NXPI
|
+$648M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$1.2B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.03B |
| 3 |
Gilead Sciences
GILD
|
+$917M |
| 4 |
Pfizer
PFE
|
+$901M |
| 5 |
Nike
NKE
|
+$872M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.88% |
| 2 | Consumer Discretionary | 14.86% |
| 3 | Financials | 14.2% |
| 4 | Technology | 12.51% |
| 5 | Industrials | 9.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1351
Toll Brothers
TOL
$14B
| $6.65M | ﹤0.01% |
247,274
-28,707
| -10% | -$807K |
|
|
ESL
1352
DELISTED
Esterline Technologies
ESL
| $6.54M | ﹤0.01% |
105,370
+9,000
| +9% | +$589K |
|
|
AIMT
1353
DELISTED
Aimmune Therapeutics
AIMT
| $6.54M | ﹤0.01% |
604,098
+115,700
| +24% | +$1.57M |
|
1354
lululemon athletica
LULU
$13.6B
| $6.51M | ﹤0.01% |
88,143
+1,384
| +2% | +$91.8K |
|
1355
OGE Energy
OGE
$9.71B
| $6.41M | ﹤0.01% |
195,648
-9,647
| -5% | -$289K |
|
|
OTIC
1356
DELISTED
Otonomy, Inc.
OTIC
| $6.4M | ﹤0.01% |
403,000
-900
| -0.2% | -$13.4K |
|
|
CTRL
1357
DELISTED
Control4 Corporation
CTRL
| $6.38M | ﹤0.01% |
782,155
-8,737
| -1% | -$67.6K |
|
|
CWEN.A
1358
DELISTED
Clearway Energy Class A
CWEN.A
| $6.33M | ﹤0.01% |
415,850
+2,500
| +0.6% | +$36.2K |
|
|
TYPE
1359
DELISTED
Monotype Imaging Holdings Inc.
TYPE
| $6.17M | ﹤0.01% |
250,420
-6,700
| -3% | -$156K |
|
|
SWC
1360
DELISTED
Stillwater Mining Co
SWC
| $6.14M | ﹤0.01% |
517,822
+32,500
| +7% | +$348K |
|
1361
Genpact
G
$5.78B
| $6.11M | ﹤0.01% |
227,745
-2,986
| -1% | -$82.1K |
|
|
ZLTQ
1362
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
| $6.1M | ﹤0.01% |
223,359
| – | – |
|
1363
Pitney Bowes
PBI
$2.28B
| $6.05M | ﹤0.01% |
340,071
| – | – |
|
1364
Erie Indemnity
ERIE
$13.4B
| $6.03M | ﹤0.01% |
60,656
-2,903
| -5% | -$277K |
|
|
ENTL
1365
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
| $5.98M | ﹤0.01% |
327,282
+65,000
| +25% | +$1.12M |
|
|
DRE
1366
DELISTED
Duke Realty Corp.
DRE
| $5.95M | ﹤0.01% |
223,134
+4,245
| +2% | +$99.8K |
|
1367
AutoNation
AN
$6.89B
| $5.91M | ﹤0.01% |
125,711
-1,800
| -1% | -$86.4K |
|
1368
Ryder
R
$10.1B
| $5.86M | ﹤0.01% |
95,875
-4,700
| -5% | -$311K |
|
|
PAY
1369
DELISTED
Verifone Systems Inc
PAY
| $5.86M | ﹤0.01% |
315,976
+59,010
| +23% | +$1.49M |
|
1370
Nu Skin
NUS
$236M
| $5.86M | ﹤0.01% |
126,805
+882
| +0.7% | +$35.5K |
|
|
MXIM
1371
DELISTED
Maxim Integrated Products
MXIM
| $5.85M | ﹤0.01% |
163,849
+15,130
| +10% | +$555K |
|
1372
Teradata
TDC
$2.57B
| $5.79M | ﹤0.01% |
231,041
-3,500
| -1% | -$92.9K |
|
1373
Check Point Software Technologies
CHKP
$13.7B
| $5.75M | ﹤0.01% |
72,200
+6,170
| +9% | +$516K |
|
1374
Insulet
PODD
$10.2B
| $5.75M | ﹤0.01% |
189,991
-1,830
| -1% | -$56.9K |
|
|
AIRM
1375
DELISTED
Air Methods Corp
AIRM
| $5.74M | ﹤0.01% |
160,200
+3,200
| +2% | +$116K |
|
Similar funds
T. Rowe Price Associates's Q2 2016 Portfolio in Review
As of Q2 2016, T. Rowe Price Associates held 2,596 positions worth $472B, up 0.75% from $468B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
T. Rowe Price Associates's Q2 2016 filing shows 95 new, 1,094 increased, 954 reduced and 84 closed positions. Its largest new stake was American Tower Corporation: 2,223,765 shares worth $246M. The largest sale was Alexion Pharmaceuticals, an estimated $1.2B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2016 buy was American Tower Corporation: 2,223,765 shares worth $246M.
- T. Rowe Price Associates added most to Mondelez International in Q2 2016, an estimated $841M increase.
- T. Rowe Price Associates's biggest Q2 2016 reduction was Alexion Pharmaceuticals, cutting an estimated $1.2B.
- T. Rowe Price Associates fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $750M.
- T. Rowe Price Associates's ten largest holdings make up 16% of its $472B portfolio in Q2 2016.
- T. Rowe Price Associates opened 95 new positions and closed 84 in Q2 2016.
- T. Rowe Price Associates's portfolio value rose 0.75% quarter-over-quarter to $472B.
Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.